Publications by authors named "J Fanikos"
Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems. Reversal agents for direct oral anticoagulants are a worthy focus for medication-use evaluations for reasons of efficacy, safety, and cost. A multidisciplinary team of experts developed 2 medication-use evaluation templates illustrating the application of professional society guidelines to the appropriate use of andexanet alfa.
View Article and Find Full Text PDFArticle Synopsis
- Pregnancy can increase the risk of thrombotic and cardiovascular events, but the study investigates this risk specifically for outpatient pregnant women with COVID-19.
- In a sample of 6,585 outpatients, only 169 were pregnant, and by 90 days post-diagnosis, two women had venous thrombosis, resulting in a low thrombotic event rate of 1.20%.
- The study concludes that while the risk of thrombotic and cardiovascular events exists, the absolute rates are low enough that widespread preventative measures may not be necessary for outpatient pregnant women with COVID-19.
Background: Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking.
Objective: This study aimed to assess annual trends in oral anticoagulant (OAC) utilization and expenditure across the United States (US) from 2014 to 2020.
Methods: We utilized the Medical Expenditure Panel Survey (MEPS) to study the trends of use and expenditures of warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban between 2014 and 2020 in the US.
Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown. We identified all hospitalized patients at our institution who were admitted with a clinically relevant DOAC DDI from 01/2021 to 06/2021.
View Article and Find Full Text PDFArticle Synopsis
- Balancing the safety and effectiveness of antithrombotic drugs in patients with gastrointestinal disorders is complex due to issues with drug absorption and increased bleeding risks.
- The review focuses on enteral antithrombotic therapy for patients with cardiovascular conditions and gastrointestinal issues, outlining risk assessment and methods to reduce gastrointestinal bleeding (GIB).
- It emphasizes the importance of teamwork in customizing antithrombotic therapy, based on medical society guidelines and the unique needs of patients with both cardiovascular and gastrointestinal conditions.